Menu

Gilteritinib and Differentiation Syndrome in AML: Recognition, Emergency Management and Monitoring

Author: medicalhalo
Release time: 2026-11-17 03:15:05

  Gilteritinib is a targeted therapy for acute myeloid leukemia(AML).Differentiation syndrome is a serious adverse event that can be fatal.Typical manifestations include fever,shortness of breath,chest tightness,rapid weight gain over a short period,lower‑limb or generalized edema.Imaging may reveal pleural effusion and pericardial effusion.Some patients develop hypotension and renal dysfunction.Fever combined with dyspnea is the most common presentation;fever alone should also raise suspicion.Prompt and standardized intervention significantly reduces mortality,while delayed management is the main factor for poor outcomes.This material is for general information only;drug indications and treatment plans must follow the prescribing information and the attending physician’s judgment.

  Most cases occur between day 3 and week 3 of treatment,with occasional delayed onset around one month.The first induction cycle carries the highest risk.Daily monitoring of body weight,blood pressure,respiratory status and blood oxygen is required during this period.Earlier onset is linked to higher risk of rapid progression and demands closer observation.If hypotension develops,fluid resuscitation should be initiated first,and interruption of gilteritinib should be considered.

  Untreated differentiation syndrome may progress to respiratory failure,cardiac tamponade or renal failure,all of which are medical emergencies.Early recognition and timely corticosteroid therapy can control the condition in most patients.When large pericardial effusion is present,drug therapy alone is insufficient and pericardiocentesis is needed to relieve compression.

  Once differentiation syndrome is suspected,immediate action is required:administer dexamethasone 10 mg every 12 hours,interrupt gilteritinib,and provide oxygen,diuretics and supportive care until symptoms resolve.The decision on whether and when to restart gilteritinib should be made by a hematologist.Corticosteroids must be given at an adequate dose and tapered slowly;premature discontinuation may cause symptom rebound.If treatment is resumed,it should start at a lower dose and be titrated gradually back to the standard dose.

  Before starting therapy,patients should be educated about the warning signs of differentiation syndrome.During the first cycle,daily weight,blood pressure and blood oxygen measurements are essential,along with accurate urine output recording.If body weight increases by more than 2 kg within two days or dyspnea occurs,patients should seek medical advice immediately instead of waiting for a scheduled follow‑up.Continuous,objective records of vital signs are valuable for early detection.

[ 免责声明 ]  本页面内容来自公开渠道(如FDA官网、Drugs官网、原研药厂官网等),仅供持有医疗专业资质的人员用于医学药学研究参考,不构成任何治疗建议或药品推荐。所涉药品可能未在中国大陆获批上市,不适用于中国境内销售和使用。如需治疗,请咨询正规医疗机构。本站不提供药品销售或代购服务。

Gilteritinib
描述
Gilteritinib is an oral small molecule tyrosine kinase inhibitor that exerts anti-tumor effects by selectively inhibiting the activity of FMS-like tyr [ 详情 ]
微信在线客服